Clinical Trials Logo

Clinical Trial Summary

This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.

Clinical Trial Description

Primary Outcome Measures: Progression free survival Secondary Outcome Measures: Overall survival Safety analysis ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05034133
Study type Interventional
Source Beijing Haidian Hospital
Contact Yuqing Huang, Director
Phone +8601082693152
Email [email protected]
Status Recruiting
Phase Phase 2
Start date September 1, 2021
Completion date August 31, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04790253 - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) Phase 3
Completed NCT00066742 - Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer Phase 2
Active, not recruiting NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Active, not recruiting NCT02046733 - Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Phase 2
Recruiting NCT04952597 - Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Phase 2
Completed NCT01457469 - Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer Phase 1
Completed NCT01999881 - Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients N/A
Recruiting NCT04829708 - Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy Phase 3
Completed NCT00470054 - Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2
Terminated NCT00084487 - Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy Phase 2